KR970010752A - 치환아미딘유도체 또는 그 약학적으로 허용되는 염 및 그것을 함유하는 혈소판 응집저해제 - Google Patents
치환아미딘유도체 또는 그 약학적으로 허용되는 염 및 그것을 함유하는 혈소판 응집저해제 Download PDFInfo
- Publication number
- KR970010752A KR970010752A KR1019960037444A KR19960037444A KR970010752A KR 970010752 A KR970010752 A KR 970010752A KR 1019960037444 A KR1019960037444 A KR 1019960037444A KR 19960037444 A KR19960037444 A KR 19960037444A KR 970010752 A KR970010752 A KR 970010752A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- carbon atoms
- substituted
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/20—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having nitrogen atoms of amidino groups acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Treatment Of Sludge (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
본 발명은 강력한 혈소판응집저해작용을 가지고, 경구투여에서의 유효성에 뛰어난 신규의 화합물을 제공하는 것을 목적으로 한 것이며, 상기 신규의 화합물이 하기 일반식(1)로 표시되는 치환아미딘유도체 또는 그염 및 이 화합물을 함유하는 혈소판저해제인 것을 특징으로 한 것이다.
상기 일반식(1)로 표시되는 화합물은, 피브리노겐길항작용에 기초한 뛰어난 혈소판응집저해작용을 가지고, 특히 경구투여에서의 유효성에 뛰어나고, 혈전증, 경피경관관동맥형성시술후 또는 경피경관관동맥재개통시술후의 재협착 또는 재폐쇄의 예방 또는 치료에 유효하다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (12)
- 일반식(1)[식 중, A는 -CON(R1)- 또는 -N(R1)CO-(R1은 수소원자 또는 탄소수 1~4의 알킬기를 표시함)을, D2, D3은 탄소원자를 표시하고, A는 D2또는 D3에 결합해 있다. B는 -CH2- 또는 -O-를 표시하고, X는 -CH- 또는 -N-을 표시함. 단, B가 -O-일 때, X는 -N-이 아니다. Z는 수소원자 또는 치환되어 있어도 되는 알킬기를 표시함. R2, R3, R4는, 수소원자, 탄소수 1~4의 알킬기, 프로파르길기, R5O(CO)- 또는 -CH2)m-Het(R5는 탄소수 1~4의 알킬기 또는 20메톡시에틸기, m은 1 또는 2를, Het는 피리딜기, 푸릴기 또는 티에닐기를 표시함)을, 또는 R2와 R3이 결합하고, 메틸렌 사슬의 임의의 위치가 탄소수 1~4의 알킬기 또는 탄소수 1~4의 알콕시기로 치환되어도 되는 -(CH2)n-W-(CH2)p-(n 및 p는 2 또는 3을, W는 결합, 또는 -CH2-, -O-, -N(R6)- 또는 -S(O)q-를, R6은 탄소수 1~4의 알킬기, 페닐기 또는 피리딜기를, q는 0, 1 또는 2를 표시함)을 표시함, 단 R2, R3, R4중 적어도 1개는, 수소원자, 탄소수 1~4의 알킬기, R5O(CO)-이외의 기로부터 선택된다]로 표시되는 것을 특징으로 하는 치환아미딘유도체 또는 그 약학적으로 허용되는 염.
- 제1항에 있어서, A가 D2에 결합해 있는 것을 특징으로 하는 치환아미드유도체 또는 그 약학적으로 허용되는 염.
- 제1항 또는 제2항에 있어서, R2와 R3이 결합해서 -(CH2)n-W-(CH2)p-이며, W가 결합, -CH2- , -O-, -S- 또는 -N(R6)인 것을 특징으로 하는 치환아미딘유도체 또는 그 약학적으로 허용되는 염.
- 제1항~제3항의 어느 한 항에 있어서, A가 NHCO- 또는 -CONH-인 것을 특징으로 하는 치환아미딘유도체 또는 그 약학적으로 허용되는 염.
- 제1항~제4항의 어느 한 항에 있어서, X가 CH-인 것을 특징으로 하는 치환아미딘유도체 또는 그 약학적으로 허용되는 염.
- 제1항~제5항의 어느 한 항에 있어서, B가 -CH2-인 것을 특징으로 하는 치환아미딘유도체 또는 그 약학적으로 허용되는 염.
- 제1항~제5항의 어느 한 항에 있어서, B가 O인 것을 특징으로 하는 치환아미딘유도체 또는 그 약학적으로 허용되는 염.
- 제1항~제4항의 어느 한 항에 있어서, X가 -N-인 것을 특징으로 하는 치환아미딘유도체 또는 그 약학적으로 허용되는 염.
- 제1항~제8항의 어느 한 항에 기재된 화합물 또는 그 약학적으로 허용되는 염을 유효성분으로서 함유하는 것을 특징으로 하는 혈소판응집저해제.
- 제1항~제8항의 어느 한 항에 기재된 화합물 또는 그 약학적으로 허용되는 염의 유효량을 투여하는 것으로 이루어진 것을 특징으로 하는 혈전증을 예방 또는 치료하는 방법.
- 제1항~제8항의 어느 한 항에 기재된 화합물 또는 그 약학적으로 허용되는 염의 유효량을 투여하는 것으로 이루어진 것을 특징으로 하는 경피경관관동맥형성시술후 또는 경피경관관동맥재개통시술후의 재협착을 예방 또는 치료하는 방법.
- 제1항~제8항의 어느 한 항에 기재된 화합물 또는 그 약학적으로 허용되는 염의 유효량을 투여하는 것으로 이루어진 것을 특징으로 하는 경피경관관동맥형성시술후 또는 경피경관관동맥재개통시술후의 재폐쇄를 예방 또는 치료하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP22309495 | 1995-08-31 | ||
JP95-223094 | 1995-08-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970010752A true KR970010752A (ko) | 1997-03-27 |
KR100225698B1 KR100225698B1 (ko) | 1999-10-15 |
Family
ID=16792745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960037444A KR100225698B1 (ko) | 1995-08-31 | 1996-08-31 | 치환아미딘유도체 또는 그 약학적으로 허용되는 염 및 그것을 함유하는 혈소판 응집저해제 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5719145A (ko) |
EP (1) | EP0760364B1 (ko) |
KR (1) | KR100225698B1 (ko) |
CN (1) | CN1062266C (ko) |
AT (1) | ATE194829T1 (ko) |
AU (1) | AU686515B2 (ko) |
DE (1) | DE69609382T2 (ko) |
DK (1) | DK0760364T3 (ko) |
ES (1) | ES2149411T3 (ko) |
NO (1) | NO305654B1 (ko) |
TW (1) | TW363051B (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4332384A1 (de) * | 1993-09-23 | 1995-03-30 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten III |
TW363051B (en) * | 1995-08-31 | 1999-07-01 | Mitsui Toatsu Chemicals | Substituted amidine derivatives and platelet aggregation inhibitor containing the same |
US6828275B2 (en) | 1998-06-23 | 2004-12-07 | Bayer Aktiengesellschaft | Synergistic insecticide mixtures |
EP0892044B1 (en) * | 1997-07-18 | 2004-12-29 | Mitsui Chemicals, Inc. | Esterase and its use for the production of optically active chroman compounds |
TR200101744T2 (tr) | 1998-12-14 | 2001-12-21 | F. Hoffmann-La Roche Ag | Fenilglisin türevleri. |
CA2353151A1 (en) | 1998-12-16 | 2000-06-22 | Boehringer Ingelheim Pharma Kg | Substituted aryl and heteroaryl derivatives, the preparation thereof and their use as medicaments |
BR0012683A (pt) | 1999-07-21 | 2002-04-16 | American Home Prod | Antagonistas bicìclicos seletivos para a integrina alfavbeta3 |
EP2670722B1 (en) | 2011-01-31 | 2016-10-12 | Council of Scientific & Industrial Research | Chiral 1-(4-methylphenylmethyl)-5-oxo-{n-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08511538A (ja) * | 1993-06-09 | 1996-12-03 | スミスクライン・ビーチャム・コーポレイション | 二環式フィブリノゲン拮抗物質 |
US5731324A (en) * | 1993-07-22 | 1998-03-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
IL110172A (en) * | 1993-07-22 | 2001-10-31 | Lilly Co Eli | Bicycle compounds and pharmaceuticals containing them |
US5629321A (en) * | 1994-10-27 | 1997-05-13 | Mitsui Toatsu Chemicals, Inc. | Bicyclic compound and platelet aggregation inhibitor containing the same |
TW363051B (en) * | 1995-08-31 | 1999-07-01 | Mitsui Toatsu Chemicals | Substituted amidine derivatives and platelet aggregation inhibitor containing the same |
-
1996
- 1996-08-07 TW TW085109661A patent/TW363051B/zh active
- 1996-08-19 US US08/699,346 patent/US5719145A/en not_active Expired - Fee Related
- 1996-08-20 AU AU62172/96A patent/AU686515B2/en not_active Ceased
- 1996-08-21 NO NO963469A patent/NO305654B1/no unknown
- 1996-08-30 AT AT96113937T patent/ATE194829T1/de not_active IP Right Cessation
- 1996-08-30 DK DK96113937T patent/DK0760364T3/da active
- 1996-08-30 EP EP96113937A patent/EP0760364B1/en not_active Expired - Lifetime
- 1996-08-30 DE DE69609382T patent/DE69609382T2/de not_active Expired - Fee Related
- 1996-08-30 ES ES96113937T patent/ES2149411T3/es not_active Expired - Lifetime
- 1996-08-31 CN CN96113341A patent/CN1062266C/zh not_active Expired - Fee Related
- 1996-08-31 KR KR1019960037444A patent/KR100225698B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR100225698B1 (ko) | 1999-10-15 |
ATE194829T1 (de) | 2000-08-15 |
EP0760364A2 (en) | 1997-03-05 |
NO963469L (no) | 1997-03-03 |
NO305654B1 (no) | 1999-07-05 |
US5719145A (en) | 1998-02-17 |
AU686515B2 (en) | 1998-02-05 |
NO963469D0 (no) | 1996-08-21 |
DE69609382D1 (de) | 2000-08-24 |
EP0760364A3 (en) | 1998-07-29 |
DE69609382T2 (de) | 2001-03-08 |
AU6217296A (en) | 1997-05-08 |
CN1062266C (zh) | 2001-02-21 |
EP0760364B1 (en) | 2000-07-19 |
DK0760364T3 (da) | 2000-10-09 |
CN1154962A (zh) | 1997-07-23 |
TW363051B (en) | 1999-07-01 |
ES2149411T3 (es) | 2000-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE122008000051I1 (de) | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel | |
ATE228115T1 (de) | Bizyklische fibrinogenantagonisten | |
DE69425431T2 (de) | 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren | |
DE69630160D1 (de) | Selektive Thrombin-Hemmer | |
EP1666469A4 (en) | INHIBITOR OF INHIBITOR-1 PLASMOGENIC ACTIVATOR | |
KR970010752A (ko) | 치환아미딘유도체 또는 그 약학적으로 허용되는 염 및 그것을 함유하는 혈소판 응집저해제 | |
NO307688B1 (no) | Anvendelse av terfenadinderivater som antihistaminmidler i et farmasøytisk preparat | |
WO2001091738A3 (en) | Naaladase inhibitors for treating amyotrophic lateral sclerosis | |
PT1157998E (pt) | Compostos heterociclicos seus intermediarios e inibidores da elastase | |
KR930703249A (ko) | 인단유도체 및 이 화합물을 함유하는 트롬복산 길항제 | |
EP0645382A4 (en) | CUMARIN DERIVATIVES AND THEIR USE. | |
KR950703941A (ko) | 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor) | |
DK0844241T3 (da) | Inhibitor af narkotisk analgetisk afhængighed/resistensudvikling | |
AR029937A1 (es) | Utilizacion de derivados de 2-aminotiazolina para la preparacion de medicamentos, derivados de 2-aminotiazolina y sus procedimientos de preparacion, las composiciones farmaceuticas que contienen dichos derivados, los compuestos intermediarios en la preparacion de dichos derivados y los procedimiento | |
DE69925225D1 (de) | Propylaxe und behandlung der arzneimittel induzierten nierenstörungen | |
EP1142875A4 (en) | CINNAMAMIDE DERIVATIVES AND DRUG COMPOSITIONS THAT INCLUDE | |
EP1179345A4 (en) | ANTI-INFLAMMATORY AGENTS AND INHIBITORS CONTAINING 1,4-DIHYDROPYRIDINE DERIVATIVES REDUCING THE INCREASE IN OCULAR VOLTAGE CAUSED BY LASER IRRADIATION | |
ATE260102T1 (de) | Benzamidin-derivate | |
KR970032857A (ko) | 약제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20020611 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |